Summit Trail Advisors LLC Sells 6,411 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Summit Trail Advisors LLC lowered its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 1.8% during the third quarter, HoldingsChannel reports. The firm owned 358,652 shares of the company’s stock after selling 6,411 shares during the quarter. Summit Trail Advisors LLC’s holdings in Hims & Hers Health were worth $6,606,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Alpha DNA Investment Management LLC acquired a new position in Hims & Hers Health during the third quarter worth $552,000. Charles Schwab Investment Management Inc. grew its position in shares of Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after acquiring an additional 218,566 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in shares of Hims & Hers Health during the 3rd quarter worth about $2,395,000. Intech Investment Management LLC bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at about $1,064,000. Finally, Quest Partners LLC lifted its stake in Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HIMS. TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday. Piper Sandler reissued a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their target price for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $20.71.

Hims & Hers Health Trading Up 4.9 %

Shares of HIMS opened at $25.33 on Friday. Hims & Hers Health, Inc. has a 12 month low of $8.02 and a 12 month high of $30.44. The firm’s 50 day moving average is $20.55 and its 200-day moving average is $19.26. The stock has a market capitalization of $5.53 billion, a PE ratio of 57.57 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue was up 77.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.04) EPS. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, COO Melissa Baird sold 58,750 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $21.04, for a total transaction of $1,236,100.00. Following the completion of the sale, the chief operating officer now directly owns 630,166 shares in the company, valued at $13,258,692.64. This represents a 8.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the transaction, the director now owns 23,917 shares in the company, valued at approximately $362,342.55. The trade was a 22.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,056,183 shares of company stock worth $21,501,682. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.